170 related articles for article (PubMed ID: 18183537)
1. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
Pollard JR
Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537
[TBL] [Abstract][Full Text] [Related]
2. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
Matagne A; Margineanu DG; Potschka H; Löscher W; Michel P; Kenda B; Klitgaard H
Eur J Pharmacol; 2009 Jul; 614(1-3):30-7. PubMed ID: 19383493
[TBL] [Abstract][Full Text] [Related]
3. Brivaracetam UCB.
Malawska B; Kulig K
Curr Opin Investig Drugs; 2005 Jul; 6(7):740-6. PubMed ID: 16044671
[TBL] [Abstract][Full Text] [Related]
4. Brivaracetam: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(4):517-22. PubMed ID: 26899665
[TBL] [Abstract][Full Text] [Related]
5. Seletracetam (UCB 44212).
Bennett B; Matagne A; Michel P; Leonard M; Cornet M; Meeus MA; Toublanc N
Neurotherapeutics; 2007 Jan; 4(1):117-22. PubMed ID: 17199025
[TBL] [Abstract][Full Text] [Related]
6. Brivaracetam for the treatment of epilepsy.
Klein P; Tyrlikova I; Brazdil M; Rektor I
Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
[TBL] [Abstract][Full Text] [Related]
7. Seletracetam enhances short term depression in vitro.
Yang X; Meehan AL; Rothman SM; Dubinsky JM
Epilepsy Res; 2015 Nov; 117():17-22. PubMed ID: 26320080
[TBL] [Abstract][Full Text] [Related]
8. Brivaracetam: new compound approved for the treatment of epilepsy.
Zaccara G
Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986
[TBL] [Abstract][Full Text] [Related]
9. Safinamide (Newron Pharmaceuticals).
Chazot PL
Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
[TBL] [Abstract][Full Text] [Related]
10. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
Gillard M; Fuks B; Leclercq K; Matagne A
Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
[TBL] [Abstract][Full Text] [Related]
11. Soretolide (Laboratoires Biocodex).
Fatope MO
Curr Opin Investig Drugs; 2001 Jun; 2(6):824-7. PubMed ID: 11572664
[TBL] [Abstract][Full Text] [Related]
12. Brivaracetam for the treatment of epilepsy in adults.
Mula M
Expert Rev Neurother; 2014 Apr; 14(4):361-5. PubMed ID: 24625006
[TBL] [Abstract][Full Text] [Related]
13. Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster.
Hamann M; Sander SE; Richter A
Eur J Pharmacol; 2008 Dec; 601(1-3):99-102. PubMed ID: 19014930
[TBL] [Abstract][Full Text] [Related]
14. Brivaracetam: a new drug in development for epilepsy and neuropathic pain.
Malawska B; Kulig K
Expert Opin Investig Drugs; 2008 Mar; 17(3):361-9. PubMed ID: 18321235
[TBL] [Abstract][Full Text] [Related]
15. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
Russo E; Citraro R; Mula M
Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
[TBL] [Abstract][Full Text] [Related]
16. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
[TBL] [Abstract][Full Text] [Related]
17. Losigamone. Dr Willmar Schwabe.
Willmore LJ
Curr Opin Investig Drugs; 2001 Dec; 2(12):1763-6. PubMed ID: 11892943
[TBL] [Abstract][Full Text] [Related]
18. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
19. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
Strzelczyk A; Klein KM; Willems LM; Rosenow F; Bauer S
Expert Rev Clin Pharmacol; 2016; 9(5):637-45. PubMed ID: 26891946
[TBL] [Abstract][Full Text] [Related]
20. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
